Linked Life Data

19531983

Source:http://linkedlifedata.com/resource/pubmed/id/19531983

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2009-7-27
pubmed:abstractText
Therapeutic drug monitoring of mycophenolate mofetil (MMF) was found to be beneficial in preventing acute rejection after kidney transplantation. The aim of this pilot prospective study was to evaluate the efficacy of MMF dose adjustment in de novo liver transplant patients receiving MMF at fixed versus concentration-controlled doses [ie, adapted to mycophenolic acid (MPA) AUC0-12h] and tacrolimus during the first 12 months posttransplant. Twenty-nine patients received steroids only up to day 10, induction therapy by lymphoglobulins followed by tacrolimus and MMF. In all patients, MPA AUC0-12h were measured on posttransplant days 7 and 14 and at months 1, 2, 3, 6, and 12. From March 2006 to March 2007, 15 patients received MMF at a fixed dose of 1 g twice a day for 12 months. From April 2007 to December 2007, MMF was given to 14 patients at a dose of 1 g twice a day until day 7 and was then adapted to reach an MPA AUC0-12h target of 30-60 mg x h/L. The proportion of MPA AUC0-12h values within the target range was similar in both groups. The proportion of patients with MPA AUC0-12h below 30 mg x h/L tended to be higher in the fixed dose group within the first month posttransplant. However, MMF dose did not differ significantly between the 2 groups at any period except month 1. MPA AUC0-12h tended to be higher in the concentration-controlled group at day 14 and month 2 and was significantly so at month 1. Tacrolimus trough concentrations tended to be lower in the concentration-controlled group at all study periods and was significantly so at month 3. At 12 months posttransplant, patient and graft survivals, acute rejection rate, and adverse events were similar in both groups. We concluded that adapting the dose of MMF resulted in a significant increase in MPA AUC0-12h at month 1. There was a trend toward a lower proportion of patients with MPA AUC0-12h below 30 mg x h/L in the concentration-controlled group. No difference in outcome was found between both groups.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1536-3694
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
31
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
451-6
pubmed:meshHeading
pubmed-meshheading:19531983-Adult, pubmed-meshheading:19531983-Aged, pubmed-meshheading:19531983-Clinical Protocols, pubmed-meshheading:19531983-Female, pubmed-meshheading:19531983-Glucuronosyltransferase, pubmed-meshheading:19531983-Humans, pubmed-meshheading:19531983-Immunosuppressive Agents, pubmed-meshheading:19531983-Liver Transplantation, pubmed-meshheading:19531983-Longitudinal Studies, pubmed-meshheading:19531983-Male, pubmed-meshheading:19531983-Metabolic Clearance Rate, pubmed-meshheading:19531983-Middle Aged, pubmed-meshheading:19531983-Mycophenolic Acid, pubmed-meshheading:19531983-Prospective Studies, pubmed-meshheading:19531983-Rejection (Psychology), pubmed-meshheading:19531983-Tacrolimus, pubmed-meshheading:19531983-Time Factors, pubmed-meshheading:19531983-Treatment Outcome
pubmed:year
2009
pubmed:articleTitle
Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses.
pubmed:affiliation
Department of Nephrology, Dialysis and Multi-Organ Transplantation, CHU Rangueil, Toulouse, France. kamar.n@chu-toulouse.fr
pubmed:publicationType
Journal Article